Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9357574 | 0.92 | LTA4H (0.70) | LTA4HMAPK14NPC1RAB9ACYP11B1 | |
| SCHEMBL105010 | 0.81 | LTA4H (1.00) | LTA4HMAPK14NPC1RAB9ACYP11B1 | |
| Bromide SCHEMBL5755659 | 0.79 | LTA4H (0.96) | LTA4HMAPK14NPC1RAB9ACYP11B1 | |
| Hydrochloric Acid SCHEMBL2655772 | 0.79 | LTA4H (0.96) | LTA4HMAPK14NPC1RAB9ACYP11B1 | |
| SCHEMBL7843486 | 0.79 | LTA4H (0.56) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11084194 | 0.79 | LTA4H (0.56) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5844763 | 0.78 | RAB9A (0.53) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6027184 | 0.78 | RAB9A (0.68) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL23850962 | 0.77 | LTA4H (0.54) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7222828 | 0.77 | CYP1A2 (0.59) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105534-B2 | Imidazo[1,2-α]pyridine ether compounds as ion channel modulators | CARDIOME PHARMA CORP. (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20040048885-A1 | Imidazo[1,2,-A]pyridine ether compounds as ion channel modulators | CORREVIO CANADA CORP. (CA) | 2004-03-11 | — | — | US | disclosed |
| WO-2001096335-A1 | IMIDAZO[1,2-A]PYRIDINE ETHER COMPOUNDS AS ION CHANNEL MODULATORS | CARDIOME PHARMA CORP. (CA) | 2001-12-20 | — | — | WO | disclosed |
| EP-0033094-B1 | IMIDAZO(1,2-A)PYRIDINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1984-10-10 | — | — | EP | disclosed |
| US-4450164-A | ANTIULCER AND ANTISECRETORY AGENTS | SCHERING CORPORATION (US) | 1984-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048885-A1 | Imidazo[1,2,-A]pyridine ether compounds as ion channel modulators | KCNJ2, KCNH2, KCNA1 | LTA4H 3402/4885MAPK14 2384/4885NPC1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.